Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 14.5% during trading on Monday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Up 3.8 %
The company has a market cap of C$23.96 million, a P/E ratio of -13.75 and a beta of 0.20. The business’s 50 day moving average is C$0.11 and its 200 day moving average is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What is a SEC Filing?
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
- What Are Dividend Champions? How to Invest in the Champions
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- How to Invest in Blue Chip Stocks
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
